TScan Therapeutics (TCRX) Competitors $1.94 -0.11 (-5.37%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. AUTL, ETHZ, ATXS, ADCT, PRTC, FDMT, YMAB, EOLS, KMDA, and AURAShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Autolus Therapeutics (AUTL), Flag Ship Acquisition (ETHZ), Astria Therapeutics (ATXS), ADC Therapeutics (ADCT), PureTech Health (PRTC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), Kamada (KMDA), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Autolus Therapeutics Flag Ship Acquisition Astria Therapeutics ADC Therapeutics PureTech Health 4D Molecular Therapeutics Y-mAbs Therapeutics Evolus Kamada Aura Biosciences TScan Therapeutics (NASDAQ:TCRX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Do institutionals & insiders hold more shares of TCRX or AUTL? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 4.4% of TScan Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate TCRX or AUTL? TScan Therapeutics presently has a consensus price target of $7.80, suggesting a potential upside of 302.06%. Autolus Therapeutics has a consensus price target of $9.12, suggesting a potential upside of 494.14%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than TScan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Autolus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is TCRX or AUTL more profitable? Autolus Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. Autolus Therapeutics' return on equity of -56.18% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,964.88% -63.33% -40.19% Autolus Therapeutics N/A -56.18%-29.61% Does the media refer more to TCRX or AUTL? In the previous week, Autolus Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Autolus Therapeutics and 0 mentions for TScan Therapeutics. Autolus Therapeutics' average media sentiment score of 1.02 beat TScan Therapeutics' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment TScan Therapeutics Neutral Autolus Therapeutics Positive Which has more risk & volatility, TCRX or AUTL? TScan Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Which has stronger valuation & earnings, TCRX or AUTL? TScan Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M39.04-$127.50M-$1.09-1.78Autolus Therapeutics$29.93M13.65-$220.66M-$0.84-1.83 SummaryAutolus Therapeutics beats TScan Therapeutics on 12 of the 16 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.10M$3.31B$6.12B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-1.7821.5685.7226.88Price / Sales39.04412.90581.25184.02Price / CashN/A46.3226.3031.10Price / Book0.4610.0213.226.67Net Income-$127.50M-$52.22M$3.30B$276.44M7 Day Performance6.59%5.57%4.78%3.10%1 Month Performance1.57%11.80%8.42%10.19%1 Year Performance-64.73%25.31%87.67%40.32% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics1.9926 of 5 stars$1.94-5.4%$7.80+302.1%-62.8%$110.10M$2.82M-1.78100AUTLAutolus Therapeutics3.8177 of 5 stars$1.59+1.9%$9.12+473.6%-60.8%$415.18M$10.12M-1.89330ETHZFlag Ship AcquisitionN/A$2.48-1.2%N/AN/A$412.72MN/A-0.167ATXSAstria Therapeutics2.6458 of 5 stars$7.36+0.8%$30.20+310.3%-35.2%$411.98MN/A-3.6630Positive NewsADCTADC Therapeutics2.9408 of 5 stars$4.02+10.0%$7.75+93.0%+34.7%$410.62M$70.84M-2.56310News CoverageAnalyst RevisionPRTCPureTech Health0.0729 of 5 stars$18.15+7.4%N/A-7.7%$408.45M$4.83M0.00100Positive NewsGap UpFDMT4D Molecular Therapeutics2.5286 of 5 stars$8.35-0.5%$30.40+264.1%-15.7%$391.83M$40K-2.37120Positive NewsYMABY-mAbs Therapeutics1.7754 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150EOLSEvolus4.0063 of 5 stars$6.14+2.5%$21.25+246.1%-60.6%$387.47M$266.27M-6.27170News CoverageKMDAKamada4.5512 of 5 stars$6.87+3.0%$13.00+89.2%+28.8%$383.56M$169.52M20.21360News CoveragePositive NewsAnalyst RevisionAURAAura Biosciences2.0466 of 5 stars$6.17+0.2%$22.00+256.6%-32.1%$382.66MN/A-3.1550News CoveragePositive News Related Companies and Tools Related Companies Autolus Therapeutics Competitors Flag Ship Acquisition Competitors Astria Therapeutics Competitors ADC Therapeutics Competitors PureTech Health Competitors 4D Molecular Therapeutics Competitors Y-mAbs Therapeutics Competitors Evolus Competitors Kamada Competitors Aura Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
